TRVI News and Press, Trevi Therapeutics Inc. From 03/25/21

Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 NEW HAVEN, Conn., March 25, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRV...

NEW HAVEN, Conn., March 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced t...

NEW HAVEN, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced th...

Trevi Therapeutics (TRVI) appointed 30-years industry veteran William Forbes, Pharm.D., as Chief Development Officer who will be responsible for leading the clinical development of Haduvio which is in late-stage clinical trials in its two lead indications."Bill's extensive experienc...

Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications NEW HAVEN, Conn., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

Trevi Therapeutics, Inc. (TRVI) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Chris Seiter – Chief Financial Officer Conference Call Participants Gary Nachman – BMO Capital Markets ...

Trevi Therapeutics (TRVI): Q3 net loss of $7.4MAs of September 30, 2020, the Company had total cash and cash equivalents of $53.3 million, compared to $57.3 million as of December 31, 2019.The Company expects its cash position will fund operations into the first half of 2022.Shares -2.3%...

PRISM Trial of Haduvio ™ for Severe Pruritus in Patients with Prurigo Nodularis Exceeds Halfway Enrollment Milestone Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject Post- COVID -19 Restrictions Cash P...

NEW HAVEN, Conn., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced th...

Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF Phase 2b/3 PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis Reaches 50% Enrollment Milestone NEW HAVEN, Conn., Oct. ...